Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C4Y0 | ISIN: KYG0028A1085 | Ticker-Symbol: 8ZD
Frankfurt
06.06.25 | 15:29
1,020 Euro
+2,51 % +0,025
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
ABBISKO CAYMAN LTD Chart 1 Jahr
5-Tage-Chart
ABBISKO CAYMAN LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,3940,47406.06.

Aktuelle News zur ABBISKO CAYMAN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS-
29.05.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS ANNOUNCES RECEIPT OF US$85MN FROM MERCK IN CONSIDERATION FOR PIMICOTINIB (ABSK021) GLOBAL ...10
26.05.China's CDE grants breakthrough status approval to Abbisko's HCC therapy1
ABBISKO CAYMAN Aktie jetzt für 0€ handeln
26.05.Abbisko Therapeutics Secures Breakthrough Therapy Designation For Irpagratinib In HCC Treatment1
26.05.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - CDE APPROVAL OF BREAKTHROUGH THERAPY DESIGNATION FOR IRPAGRATINIB (ABSK011) OF ABBISKO THERAPEUTICS IN THE ...3
23.05.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ORAL PRESENTATION BY ABBISKO THERAPEUTICS ON RESULTS OF PIMICOTINIB IN TGCT FROM THE PHASE 3 MANEUVER STUDY ...1
22.05.ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS-
20.05.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS' CSF-1R INHIBITOR, PIMICOTINIB (ABSK021), HAS BEEN GRANTED PRIORITY REVIEW FOR TGCT ...2
16.05.ABBISKO-B (02256): FORM OF PROXY FOR THE 2024 ANNUAL GENERAL MEETING-
16.05.ABBISKO-B (02256): NOTICE OF THE ANNUAL GENERAL MEETING1
16.05.ABBISKO-B (02256): PROPOSALS FOR GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND TO REPURCHASE SHARES RE-ELECTION OF DIRECTORS RE-APPOINTMENT OF AUDITOR ...1
14.05.ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS-
13.05.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS TO PRESENT UPDATED RESULTS FROM THE PHASE 2 STUDY OF IRPAGRATINIB IN COMBINATION WITH ...1
06.05.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE FOUNDER, THE EXECUTIVE DIRECTOR, THE CHIEF EXECUTIVE OFFICER ...-
06.05.ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS3
29.04.ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS2
28.04.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTS FOUR LATE-BREAKING PRE-CLINICAL RESEARCH RESULTS ON ABSK112 (EGFR EXON20INS), ...2
22.04.ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS1
17.04.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - AMENDMENTS TO THE POST-IPO RSU SCHEME AND THE POST-IPO SHARE OPTION SCHEME1
15.04.ABBISKO-B (02256): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT1
Weiter >>
47 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1